A Dedicated Oncology Cluster. Ketil Widerberg, General Manager, Oslo Cancer Cluster




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: A Dedicated Oncology Cluster. Ketil Widerberg, General Manager, Oslo Cancer Cluster
Released on: October 31, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Ketil Widerberg, General Manager, Oslo Cancer Cluster
  • Summary
  • Transcript
  • Participants
  • Company
Ketil Widerberg, General Manager, Oslo Cancer Cluster
Ketil Widerberg, General Manager, Oslo Cancer Cluster
Ketil Widerberg
Oslo Cancer Cluster
Oslo Cancer Cluster

Oslo Cancer Cluster is an oncology research and industry cluster dedicated to accelerating the development of new cancer diagnostics and medicines. We gather almost 70 members from Norway and Northern Europe representing the entire oncology value chain. As a Norwegian Centre of Expertise, the Norwegian government partially funds the cluster. An evaluation from 2013 states that Oslo Cancer Cluster is a strong biotech cluster well positioned in the global oncology industry. Major industry trends now offer a unique opportunity to strengthen the cluster’s position as a global knowledge and innovation centre. Accelerating the development of cancer treatments Oslo Cancer Cluster was established in 2006 and received the status as a Norwegian Centre of Expertise in 2007. Our members include academic research institutions, biotech companies, pharmaceutical companies, university hospitals, universities, support groups, financial institutions and regional development players in the field of cancer R&D. Together the members work to fulfill Oslo Cancer Clusters vision: «We are committed to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.» Four out of ten will be diagnosed with cancer during life and it is crucial to develop new diagnostics and medication. Please read more about our strategy and vision and projects to learn more about how we strive to make a difference for cancer patients. Core expertise: Immuno-Oncology Oslo Cancer Cluster has core expertise in the field of Immuno-Oncology. The cluster is building an exciting pipeline of novel cancer immunotherapies in preclinical and clinical development – and is well positioned to contribute to the global race in this area. Oslo Cancer Cluster established the Norwegian Immuno-Oncology Consortium in 2013 and is developing this area further in close collaboration with its members. Early clinical trials in oncology is also an area of high importance for the cluster, and are performed both at the Clinical Cancer Research Unit at Oslo University Hospital and at the Clinical Trial Unit at Haukeland University Hospital. Other centers in Norway are alo performing clinical trials.